Last update 01 Nov 2024
Suzhou Xinda Biotechnology Co., Ltd.

Suzhou Xinda Biotechnology Co., Ltd.

Private Company|
2013|
Jiangsu Sheng, China
|
cn.innoventbio.com

Overview

Tags

Otorhinolaryngologic Diseases
Digestive System Disorders
Respiratory Diseases
Monoclonal antibody
Biosimilar

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Monoclonal antibody1
Biosimilar1
Top 5 TargetCount
CTLA4(Cytotoxic T-Lymphocyte-Associated Antigen 4)1

Related

1
Drugs associated with Suzhou Xinda Biotechnology Co., Ltd.
Ipilimumab biosimilar (Innovent Biologics)
Target
CTLA4
Mechanism
CTLA4 inhibitors
Active Org.
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (Suzhou) Co. Ltd. [+1]
Originator Org.
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (Suzhou) Co. Ltd.
Active Indication
Microsatellite instability-high Colonic Cancer [+8]
Inactive Indication
Acral Lentiginous Malignant Melanoma [+5]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
5
Clinical Trials associated with Suzhou Xinda Biotechnology Co., Ltd.
CTR20231430 / RecruitingPhase 1
评估IBI310 联合信迪利单抗新辅助治疗可切除的高度微卫星不稳定型（MSI-H）或错配修复缺陷型（dMMR）结肠癌的有效性和安全性的Ib/III 期研究
[Translation] A phase Ib/III study to evaluate the efficacy and safety of IBI310 combined with sintilimab in the neoadjuvant treatment of resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer
CTR20223243 / RecruitingPhase 1/2
IBI310（抗-CTLA-4）联合信迪利单抗用于标准治疗后进展的晚期胆道癌的单臂、多中心、Ib/II期研究
[Translation] A single-arm, multicenter, phase Ib/II study of IBI310 (anti-CTLA-4) combined with sintilimab for advanced biliary tract cancer that has progressed after standard therapy
CTR20212823 / CompletedPhase 1
IBI310（抗CTLA-4）联合信迪利单抗治疗晚期或转移性非小细胞肺癌的开放、多中心、Ib期研究
[Translation] An open, multicenter, phase Ib study of IBI310 (anti-CTLA-4) combined with sintilimab in the treatment of advanced or metastatic non-small cell lung cancer
100 Clinical Results associated with Suzhou Xinda Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Suzhou Xinda Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Suzhou Xinda Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Suzhou Xinda Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 24 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Ipilimumab biosimilar (Innovent Biologics)
 ( CTLA4 )		Nasopharyngeal Carcinoma
More
Phase 2 Clinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free